TABLE 7

Potential therapeutic application of EP₃ antagonists

Antagonist	Route	Dose	Species	Experimental Model	Indication	Reference
DG-041	Intravenous	10 mg/kg	Rat	Urinary bladder distension	Overactive bladder	Su et al., 2008a
DG-041	Oral	0.1–100 mg/kg	Rat	Ex vivo platelet aggregation; bleeding time	Atherothrombosis	Singh et al., 2009
L-826266	Intraperiaqueductal grey	0.125 nM–0.5 nM	Mouse	Formalin induced hyperalgesia	Pain	Oliva et al., 2006
L-826266	Intraplantar	3–30 nmol	Mouse	Paw-licking	Rheumatoid arthritis	Kassuya et al., 2007
ONO-AE3-240	Subcutaneous	3.30 mg/kg	Mouse	HSV-1 inoculation	Post-herpetic pain	Takasaki et al., 2005
ONO-AE3-240	Subcutaneous	50 nmol/tumor	Mouse	Sarcoma 180 cell tumor	Cancer	Amano et al., 2003